AMR is such a big concern that the true measurement of its global impact is unfathomable. Presently, most of the controlling and regulatory bodies across the globe talk about regional AMR prevalence based on a limited sample of clinical isolates.
AMR is a resultof non-performance of drugs not only on humans but also on animals and flora. The ever-rising use of toxic chemicals in soaps, detergents, agriculture chemicals, the untreated lab waste from veterinary care centers, hospital discharges, unhygienic practices, irrational use, easy availability of antibiotic drugs in certain parts of the world and other unaccounted exposures all contribute to the spread of resistance. The sources are beyond control. All this cumulative unwanted exposure of drugs/ chemicals to pathogens is so enormous that microbes over smart the development cycle of new drugs.
Therefore, quantifying the global economic impact of AMR is not simple, however, a conservative estimate of the total economic output loss if resistance is left unchecked is around $100 trillion globally by 2050. It is safe to say that if immediate actions are not taken, it will lead to a pre-antibiotic era where common infections will kill again. Different types of bacteria are resistant to different classes of antibiotics. while some bacteria are resistant to all classes of antibiotics. Such multi-drug resistance poses the greatest threats.
Resistance is a greater problem in low and middle income countries, primarily due to the easily availability and overuse of antibiotics. Reports suggest that only 13 million people who need antibiotics have access to them as compared to 27 million people who get antibiotics unnecessarily .
40% in global antibiotic consumption b/w 2000 - 2010
75% of this increase is from BRIC + South Africa
45% deaths in Africa are due to infections
50,000 deaths/year in USA and Europe alone
By 2030, 100 million premature deaths due to AMR
By 2050 - 10 million people are estimated to die each year
if resistance continues to grow at the present rate
Many procedures, such as hip operations, cancer
treatments would become a much riskier proposition
By 2050 - $100 trillion loss in global GDP (cumulative)
Unless otherwise specified, all product names appearing in this internet site are trademarks owned by or licensed to VRL India, its subsidiaries or affiliates. No use of any VRL India trademark, trade name, or trade dress in this site may be made without the prior written authorization of VRL India, except to identify the product or services of the company.